Publicaciones en colaboración con investigadores/as de Complejo Asistencial Universitario de Burgos (12)

2024

  1. Incidence and outcoMes of MInor stroke and high-risk traNsient ischEmic attack in NordicTus. IMMINENT study

    Neurologia

2021

  1. Delayed Neurological Improvement After Full Endovascular Reperfusion in Acute Anterior Circulation Ischemic Stroke

    Stroke, Vol. 52, Núm. 7, pp. 2210-2217

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Impact of COVID-19 outbreak in reperfusion therapies of acute ischaemic stroke in northwest Spain

    European Journal of Neurology, Vol. 27, Núm. 12, pp. 2491-2498

  3. Impact of COVID-19 outbreak on ischemic stroke admissions and in-hospital mortality in North-West Spain

    International Journal of Stroke, Vol. 15, Núm. 7, pp. 755-762

  4. Oral Anticoagulation and Risk of Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Mechanical Thrombectomy: Data From the Nordictus Registry

    Frontiers in Neurology, Vol. 11

2018

  1. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy

    HIV Clinical Trials, Vol. 19, Núm. 5, pp. 197-201

2017

  1. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

    Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis

    Cerebrovascular Diseases, Vol. 26, Núm. 2, pp. 126-133

  3. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2007

  1. Impacto de la reducción de dosis de estavudina en su perfil de eficacia/seguridad en pacientes con infección por el virus de la inmunodeficiencia humana inmunológica y virológicamente estables

    Medicina Clinica, Vol. 129, Núm. 10, pp. 361-365